| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5803eb2958ba7d229ec90118f47f60b2 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-755 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-745 |
| filingDate |
2013-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d36292a48fae7c00f53c27cba600b281
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_299c932d6247d5b3eeeb4a36b4179ebd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c87b423c1802d5a8f587d7726d6debd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1697faea2ad9a43ff42baf9a29d1dca7 |
| publicationDate |
2014-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2014083510-A1 |
| titleOfInvention |
Monolith-based pseudo-bioaffinity purification methods for factor viii and applications thereof |
| abstract |
The present disclosure relates to purification of Factor VIII protein and/or its fragments from various sources by employing monolith based pseudobioaffinity purification methods. In particular, L-histidine over CIM monolith [Histidine Ligand Affinity Chromatography (HLAC)] is used for the purification of wild-type factor VIII from plasma cryoprecipitate, recombinant B-domain deleted factor VIII (rBDD-FVIII) expressed in various host systems and recombinant factor VIII light chain expressed in Pichia pastoris . Further, immobilized metal over CIM monolith [Immobilized metal-ion affinity chromatography (IMAC)] is employed for the purification of wild-type factor VIII, rBDD-FVIII expressed in various host systems and recombinant factor VIII heavy chain expressed in Pichia pastoris . The purification efficiency showcased by the purification methods of the present disclosure is far superior when compared to the presently available methods for the purification of factor VIII which lead to significantly improved results in therapeutic applications involving factor VIII. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2734783-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10889630-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023148172-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IL-261034-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IL-261034-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2017218581-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017137583-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7144113-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4223381-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019511467-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3205665-A1 |
| priorityDate |
2012-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |